stoxline Quote Chart Rank Option Currency Glossary
  
SI-BONE, Inc. (SIBN)
16.37  0.55 (3.48%)    03-28 16:00
Open: 16.71
High: 16.84
Volume: 496,850
  
Pre. Close: 15.82
Low: 16.21
Market Cap: 672(M)
Technical analysis
2024-03-28 4:54:15 PM
Short term     
Mid term     
Targets 6-month :  21.6 1-year :  24.22
Resists First :  18.5 Second :  20.73
Pivot price 16.17
Supports First :  14.88 Second :  12.38
MAs MA(5) :  15.57 MA(20) :  16.51
MA(100) :  18.77 MA(250) :  21.22
MACD MACD :  -0.9 Signal :  -1
%K %D K(14,3) :  29.2 D(3) :  16.3
RSI RSI(14): 42.6
52-week High :  29.51 Low :  14.88
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SIBN ] has closed below upper band by 43.4%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.87 - 16.93 16.93 - 17
Low: 16.05 - 16.12 16.12 - 16.19
Close: 16.26 - 16.38 16.38 - 16.5
Company Description

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Headline News

Fri, 29 Mar 2024
SI-BONE (NASDAQ:SIBN) Receives New Coverage from Analysts at Piper Sandler - Defense World

Fri, 29 Mar 2024
Critical Contrast: Presbia (OTCMKTS:LENSF) vs. SI-BONE (NASDAQ:SIBN) - Defense World

Thu, 28 Mar 2024
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights - Markets Insider

Thu, 28 Mar 2024
SI-BONE (NASDAQ:SIBN) Shares Gap Up to $15.82 - MarketBeat

Thu, 14 Mar 2024
Si-Bone executive sells over $56,000 in company stock By Investing.com - Investing.com

Thu, 29 Feb 2024
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 41 (M)
Shares Float 38 (M)
Held by Insiders 2.4 (%)
Held by Institutions 97.9 (%)
Shares Short 2,320 (K)
Shares Short P.Month 1,750 (K)
Stock Financials
EPS -1.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.15
Profit Margin -31.3 %
Operating Margin -32.2 %
Return on Assets (ttm) -15.2 %
Return on Equity (ttm) -32.4 %
Qtrly Rev. Growth 21.6 %
Gross Profit (p.s.) 0
Sales Per Share 3.38
EBITDA (p.s.) -1.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -19 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -14.49
PEG Ratio -1.8
Price to Book value 3.93
Price to Sales 4.83
Price to Cash Flow -35.93
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android